Knight Therapeutics Inc. (KHTRF)

Market Cap	430.65M +7.5%
Revenue (ttm)	297.11M +18.7%
Net Income	-2.51M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	188.79
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400
Average Volume	5,761
Open	4.330
Previous Close	4.330
Day's Range	4.330 - 4.330
52-Week Range	3.791 - 4.720
Beta	0.13
RSI	55.26
Earnings Date	Mar 19, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: OTCMKTS
• Ticker Symbol: KHTRF

Financial Performance

Financial numbers in CAD